We should expect an announcement about those case control studies very soon if assay development is to commence in Q4 2019.
From 2018 Annual Report.
Further case-control studies are plannedfor 2019 to optimise the BARD1-Lung test using the new multiplex BARD1 assay,additional biomarkers and gender-specific algorithms, followed by developmentand analytical validation of the refined BARD1-Lung on Luminex®instrumentation, before advancing towards clinical studies.
Performance Shares, page-7
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
50.0¢ |
Change
-0.025(4.76%) |
Mkt cap ! $55.76M | |||
| Open | High | Low | Value | Volume |
| 53.0¢ | 53.0¢ | 50.0¢ | $160.3K | 315.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 40373 | 49.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.0¢ | 9050 | 1 |
View Market Depth
| Last trade - 15.58pm 13/09/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |